ARTHUR S. KIRSCH - 20 Feb 2025 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Director
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Arthur S. Kirsch
Issuer symbol
AVIR
Transactions as of
20 Feb 2025
Net transactions value
$0
Form type
4
Filing time
24 Feb 2025, 18:52:21 UTC
Previous filing
24 Jun 2024
Next filing
20 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Stock Option (Right to Buy) Award $0 +164,800 $0.000000 164,800 20 Feb 2025 Common Stock 164,800 $3.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in thirty-six (36) equal monthly installments following February 20, 2025 such that the option is fully vested on February 20, 2028.